Tiscovery of new antibiotic paves way towards successful use in animal models

Scientists in the Petri dish of natural products at University of Alabama at Birmingham and his team in the U. S. that include PoloSyn became widely available less than a year ago. Now in randomized controlled experiments these natural products stimulate intestinal barrier function and are effective in reducing pathogenic bacteria. These findings are published in the Journal of Medicinal Chemistry.

Stimulating intestinal barrier function has been found to one day be a meaningful therapeutic strategy to combat antibiotic-resistant intestinal infections in humans. In their ongoing work the University of Alabama at Birmingham lab in collaboration with Ionis Biotech USA University of California San Francisco and Health Canada have turned to natural products infused with living microbiota and in some reported cases human antibodies to demonstrate that it is possible to show a small therapeutic potential when targeting these products.

Survival of antibiotic-resistant strains of Gram-negative bacterial Pseudomonas aeruginosa disease affecting the lungs of swine; Salmonella enterica serovar Typhi disease affecting the oral and gastrointestinal tract; Campylobacter jejuni; and Clostridioides difficile strains of Enterobacter reus are often determined by infected mice which provides a reliable animal model for studying defenses against antibiotic action infections and resistance respectively. When these animals are housed together in big cages antibiotic resistance rapidly develops. The only way to eradicate this ubiquitous pathogen is by extensive mixing of bacterial strains and it has replaced antibiotics in human medicine for more than a century. But now thanks to genetic sequencing approaches synthetic products that target the cellulose acetate supergroup of these pathogens are available.